🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Biofil Chemicals and Pharmaceuticals Limited BIOFILCHEM NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.biofilgroup.net
Company Profile ↓
₹32.00
-27.07% 1Y
Mkt Cap₹52.08 Cr
P/E18.71
P/B2.45
52W High₹46.34
52W Low₹25.79
Book Value₹13.25
EPS (TTM)₹1.71

Company Overview

Biofil Chemicals and Pharmaceuticals Limited engages in manufacturing and trading of pharmaceuticals in India. It operates through Pharmaceutical and Chemical divisions. The company offers basic drugs and chemicals, such as sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine citrate, ferrous sulphate, dried ferrous sulphate, ferrous fumerate, micro crystalline cellulose, and dicyclomine hydrochloride; and packaging solutions. It also provides job work service for manufacturing pharmaceutical drugs. Biofil Chemicals and Pharmaceuticals Limited was incorporated in 1985 and is based in Indore, India.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 15.6%.

Consistent Profit Growth

Net profit has compounded at 70.7% per year over the last five years.

Reasonable Valuation

Trades at a P/E of 18.7, below the sector median of 41.6.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.14.

Recent Developments

  • Mar 2026 Revenue of ₹28.40 Cr (-15.0% YoY); net profit ₹2.79 Cr.
  • Trailing 12 Months Year-on-year growth — revenue -15.0%, earnings +399.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR -1.9%, profit CAGR 70.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-1.85%
1 Year:-14.99%

Compounded Profit Growth

5 Years:70.67%
1 Year:399.46%

Stock Price Performance

1 Year:-27.07%
6 Months:+3.73%
3 Months:-11.63%
1 Month:-0.71%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 30% of range
₹25.79 ₹46.34
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)46.64 · Neutral
Price Performance
1M-0.71%
3M-11.63%
6M+3.73%
1Y-27.07%
Valuation vs Sector

P/E of 18.71 is below the sector median of 41.64 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Profit CAGR of 70.7% over 5 years.

CONS

  • Revenue declined at -1.9% CAGR over 5 years.
  • Trading 30.9% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
18.71
Industry PE
41.64
Forward P/E est.
9.36
PEG Ratio
-
Book Value
₹13.25
Price to Book
2.45
P/S
1.67
EV/EBITDA
14.09
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-1.85%
Profit 5Y
70.67%
Revenue (YoY)
-14.99%
Earnings (YoY)
399.46%

Profitability & Returns

ROCE
15.61%
ROE
12.92%
ROA
6.50%
Profit Margin
9.81%
Op Margin
1.33%
Gross Margin
7.42%
EPS (Latest Qtr)
₹0.00
EPS (TTM)
₹1.71

Balance Sheet & Liquidity

Debt/Equity
0.14
Quick Ratio
1.54
Current Ratio
1.73
Debt
₹3.02 Cr
Total Assets
₹42.85 Cr
Current Assets
₹35.86 Cr
Working Capital
₹15.17 Cr

Ownership

Promoter Holding
58.08%
Chg in Prom Hold
-0.44%
FII / Inst Holding
0.00%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹52.08 Cr
Total Revenue (TTM)
₹28.40 Cr
EBITDA
₹3.73 Cr
Free Cash Flow
₹-80.54 L
Operating Cash Flow
₹-60.49 L
Shares Outstanding
₹1.63 Cr
Gross Margin
7.42%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 BIOFILCHEM Biofil Chemicals and Pharmaceuticals Limited NSEPHARMA 32.00 18.71 ₹52.08 Cr 0.00% 15.61% 12.92% -1.85% 70.67%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue --8.35 Cr6.43 Cr13.54 Cr85.63 L7.57 Cr
Cost of Revenue --7.80 Cr5.99 Cr13.17 Cr42.50 L6.64 Cr
Gross Profit --54.71 L44.30 L36.96 L43.13 L92.74 L
Operating Expenses --52.25 L50.32 L32.12 L40.24 L56.69 L
Operating Income --2.46 L-6.02 L4.84 L2.89 L36.05 L
EBITDA --34.47 L2.84 Cr17.78 L17.32 L54.31 L
Interest Expense --75,00093,0001,0005,0002,000
Pretax Income --25.38 L2.76 Cr11.17 L10.67 L46.88 L
Tax Provision --5.41 L35.15 L2.81 L2.75 L25.66 L
Net Income --19.97 L2.41 Cr8.36 L7.92 L21.22 L
Diluted EPS 0.01-0.121.480.050.050.00

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -30.04 Cr40.04 Cr33.40 Cr28.40 Cr
Cost of Revenue -27.42 Cr38.12 Cr31.31 Cr26.29 Cr
Gross Profit -2.61 Cr2.53 Cr2.09 Cr2.11 Cr
Operating Expenses -1.87 Cr2.11 Cr1.62 Cr1.73 Cr
Operating Income -73.86 L41.72 L46.79 L37.74 L
EBITDA -1.26 Cr1.31 Cr1.15 Cr3.73 Cr
Interest Expense -4.19 L4.15 L3.69 L1.01 L
Pretax Income -79.30 L86.53 L73.61 L3.45 Cr
Tax Provision -23.26 L15.61 L17.83 L66.36 L
Net Income -56.04 L70.92 L55.78 L2.79 Cr
Diluted EPS -0.340.440.341.71

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -31.41 Cr47.08 Cr50.96 Cr42.85 Cr
Current Assets -22.35 Cr38.41 Cr42.55 Cr35.86 Cr
Cash & Equivalents -3.77 L2.28 Cr25.53 L6.38 L
Inventory -1.21 Cr2.55 Cr3.34 Cr4.00 Cr
Receivables -20.50 Cr33.03 Cr38.31 Cr27.59 Cr
Total Liabilities -14.10 Cr28.88 Cr32.18 Cr21.28 Cr
Current Liabilities -13.73 Cr28.52 Cr31.85 Cr20.69 Cr
Long Term Debt -----
Total Debt -52.23 L43.89 L47.13 L3.02 Cr
Total Equity -17.30 Cr18.20 Cr18.78 Cr21.56 Cr
Shares Outstanding -1.63 Cr1.63 Cr1.63 Cr1.63 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow --11.18 L2.39 Cr-1.92 Cr-60.49 L
Investing Cash Flow --1.06 L-2.29 L-10.01 L1.14 Cr
Financing Cash Flow -1.51 L-12.49 L-45,0002.54 Cr
Capital Expenditure --1.06 L-2.29 L-10.01 L-20.05 L
Free Cash Flow --12.24 L2.37 Cr-2.02 Cr-80.54 L
Net Change in Cash --10.73 L2.25 Cr-2.03 Cr3.07 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -8.7%6.3%6.3%7.4%
Operating Margin % -2.5%1.0%1.4%1.3%
Net Margin % -1.9%1.8%1.7%9.8%
ROE % -3.2%3.9%3.0%12.9%
ROCE % -4.2%2.2%2.4%1.7%

Shareholding Pattern

Insiders
58.08%
Institutions
0.00%
Public Float
0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for BIOFILCHEM

Google News Mon, 02 Feb 2026

Market Still Lacking Some Conviction On Biofil Chemicals and Pharmaceuticals Limited (NSE:BIOFILCHEM) - simplywall.st

<a href="https://news.google.com/rss/articles/CBMijAJBVV95cUxNVGJ1dS1RaDhMalR6WGxtZW1GVTF6dXh1TUV1MlZJTzRaWkZvbUkxdlgyT2E2S213YUxxZEJTUUN6dm5JSl9XejBOYXVjLTJfbzJ6MS1XSXo2OVJFM1VReG8tUlV1eWdJYmQ1MVF0ZUFHWnVRZ0ZqWmJyTjZTRW40azJFUXN6VzJVU0p2aE…

Google News Mon, 29 Jun 2026

BIOFILCHEM Q2 2026 Earnings: Revenue Decline Amidst Challenging Environment - Net Profit Margin - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxONTNRTFdoWU1KQ1NneG1WWDFVMnpxdU1iRGQ5YWROTEtwZUotazdOLUg1UnduSUxvUTRiQU8ydlJCVWk3c19KbGlWX3hsUmt4MXZ0SWxRZE9XVEhrak9JQmRXR25fQ3ozZG1VTWMzbUoxMnBzdkN4SEd1UWFjOF81eWU0VWY4Ql96aUdFbG…

Google News ue, 25 Aug 2026

Biofil (BIOFILCHEM.NS) Technicals: Moves 0.87% Lower to ₹32.06 at the Close; Next Test: the ₹30.46 to ₹33.66 Range Remains in Focus in Latest Trading - Fibonacci Time Zone - siam.in

<a href="https://news.google.com/rss/articles/CBMiigJBVV95cUxPbXFZU2lEMnZSeG1aM2pEOW05X3lnYXRMUWhlU0RIdkFIeWxRV2ZEbEliV0RqcmJOUGEtX0g1ZUlQR1E0Y2ZmYjJOM3A5cGtDRS0tcmpqQm5sNm5WZmtpLUk0eDgzU05LOFpkdkszcHB0RUo3VjR4d1NBWVNuR3kwQUJrWW51YlhzemVCcW…

Google News Sat, 13 Jun 2026

Biofil Chemicals & Pharmaceuticals (BIOFILCHEM.NS) Q2 2026 Earnings: Revenue Decline Weighs on Performance but EPS Holds Firm - Share Repurchase Impact - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMi9AFBVV95cUxNZkZZQ1dsSDdidHp5NGQtQ1lXLUtxZ0ltTVRzcUhka2VIZlh4TFNDZmVsaXV0QXlFd0wzczl4SGNOc3NZcl9QTVNuM0FXQi12MHhKaktDYjdLMnY0OEpuUENrZTZHS0lzazRpNUJacUxxTURqRHE3aExIcGhpMEw1ZFAyRTA5bWxTTzFaVm…

Google News Wed, 01 Jul 2026

BIOFILCHEM Q2 FY2026 Earnings: Revenue Declines 15% YoY While EPS Remains Positive - Dividend Earnings Report - siam.in

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPeTBscFg2TUNlV2JUYkVyQmlRcEVFdlM5MG9DWFJ5T3JpQ29iR0pTSkllUmxNa2xJYUoyWE82SDgtaHZpQVFfN2IzZWpCLTh4eUIzSmNDd2R2dTJicUxQWXplVjZyeUN6NlJhUGl6b3owWlFGaWlWSmpERHpKN2dhODF6bzgzSE95cDIzOU…

Google News Mon, 29 Jun 2026

Biofil Chemicals (BIOFILCHEM.NS) experiences marginal decline; support and resistance levels in focus - Earnings Breakout Stocks - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNNW03al8zVXE2V19WLXRwRHlQbW1HNmM0cUdUdTVRWHRmYjlpNXBVZTlGRTU4QUVZMUFvdklLQWd5S0hUOTNnUUxxTUVYV2JwdGFNUkpJTUtHUU5LUGdxYTdHd2F5ZGZvVGFTMjVuWnVzUDVyUjN6OXR6dVUzR2Q4TGl3NThEZ0M5TTBmTD…

BIOFILCHEM — Frequently Asked Questions

What is the current share price of Biofil Chemicals and Pharmaceuticals Limited (BIOFILCHEM)?

As of 2026-09-08 04:53 IST, Biofil Chemicals and Pharmaceuticals Limited (BIOFILCHEM) trades at ₹32.00 on NSE. Its 52-week range is ₹25.79 to ₹46.34.

What is the market capitalisation of BIOFILCHEM?

Biofil Chemicals and Pharmaceuticals Limited (BIOFILCHEM) has a market capitalisation of ₹52.08 Cr on NSE.

What is the P/E ratio of BIOFILCHEM?

BIOFILCHEM trades at a trailing price-to-earnings (P/E) ratio of 18.71. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 2.45.

What is the return on equity (ROE) of BIOFILCHEM?

BIOFILCHEM has a return on equity (ROE) of 12.92%. Its return on capital employed (ROCE) is 15.61%.

Is BIOFILCHEM a good stock to buy?

This page provides a data-driven analysis of Biofil Chemicals and Pharmaceuticals Limited (BIOFILCHEM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space